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Abstract
Antisense oligonucleotides (ASOs) have been validated as therapeutic agents 
and an important tool in molecular biology. Indeed, ASOs are used either in vitro or 
in vivo to generate mRNA selective knockouts. They can be used for human therapy 
since ASOs can inhibit specifically target genes especially whose are difficult to 
target with small molecules inhibitors or neutralizing antibodies. However, despite 
their specificity and broadness of use, some practical obstacles remain unsolved in 
antisense pharmacology, such as insufficient stability due to nucleases degradation 
activity, and poor cellular delivery as a result of low cellular uptake difficult biologi-
cal membrane crossing. Moreover, in many cases, potential off-target effects and 
immunostimulation are also part of the problems derived from their use. In this 
review, we will discuss ASOs, their chemistry, limitation of use, some solutions to 
increase stability, and finally some of their therapeutical application.
Keywords: antisense oligonucleotide, ASO chemistry, ASO delivery,  
therapeutic target, cancer
1. Introduction
The usage of nucleic acids in therapeutics is founded on the inhibition of RNA 
expression and on their capacity to modulate the expression of a target protein asso-
ciate to a disease [1]. ASOs are typically modified synthetic nucleic acids. They are 
single stand oligonucleotide with 16-mer to 21-mer sequence with high affinity for 
a specific RNA target sequence, through base pairing [2]. The two general chemical 
classes of nucleic acids commonly used today are antisense oligonucleotides (ASOs) 
and siRNA. The first is single-stranded, and modulates RNA function either by 
degrading the RNA sequence in question due to enzyme RNase H activity, or by 
modifying splicing function thus affecting RNA metabolism; and the second is 
double-stranded synthetic oligonucleotides that degrade target RNA through an 
RNA-induced silencing complex (RISC). Importantly, both must reach the nucleus 
and/or cytoplasm to exert their activity, and thus must cross a biological membrane.
Although ASOs and siRNA share similarities, they are divergent on some points, 
and so, choosing ASO or siRNA strategy for gene targeting depends on the target 
gene. However, since ASOs are single stranded, as opposed to siRNA, they have 
lower cost of production. Moreover, it is easier to deliver ASOs in vivo, since they 
do not a vector and a simple chemical modification can increase their resistance 
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to nucleases, as opposed to siRNA that need a carrier. Finally, for in vitro studies, 
siRNA is considered a better technology, since it’s relatively easier to obtain a potent 
siRNA since unmodified RNA works with high potency as opposed to ASOs.
In this review we will mainly focus on ASOs chemistry and mechanism of action.
Indeed, since Zamecnik in 1978 used an ASO-like unmodified DNA sequence in 
cell culture, notable progress has been made in ASO pharmacology [3]. Currently, 
the efficacy of different ASOs is being studied in many neurodegenerative diseases 
such as Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and amyo-
trophic lateral sclerosis but also in several cancer states. Numerous ASO-based 
therapeutics are being tested in clinical trials. In Table 1 figures some of the ASO in 
clinical trial for cancer treatments. However, until now, only two ASOs have been 
approved by the US FDA to be used on humans, namely, fomivirsen (Vitravene), 
Table 1. 
Registered clinical studies with ASO in cancer treatments in clinical trials.gov.
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a first-generation ASO for cytomegalovirus (CMV) retinitis, and mipomersen 
(Kynamro), a second-generation ASO for homozygous familial hypercholesterol-
emia (HoFH) [4, 5], both developed by Isis Pharmaceuticals. They work via RNase 
H-mediated cleavage of the targeted RNA.
2. ASO’s design, chemistry and mechanism of action
2.1 ASO’s mechanism of action
Two major mechanisms contribute to the antisense activity. The first is that 
most ASOs are designed to activate RNase H, which cleaves the RNA moiety of a 
DNA–RNA heteroduplex and therefore leads to degradation of the target mRNA in 
the nucleus and cytoplasm. In addition, ASOs that do not induce RNase H cleavage 
can be used to inhibit translation by steric blockade of the ribosome in the cyto-
plasm [6]. When the ASOs are targeted to the 5′-terminus, binding and assembly of 
the translation machinery can be prevented [7]. Most mammalian RNAs undergo 
multiple post-transcriptional processing steps in the cell nucleus including addition 
of a 5′-cap structure, splicing and polyadenylation.
Regulation of RNA processing is another efficient mechanism in which ASOs 
can be utilized to regulate gene expression. Studies have been published document-
ing that ASOs can be used to destabilize pre-mRNA [8] and to regulate RNA splic-
ing [9]. Another viable approach to reversibly ‘switch’ protein function is alternative 
splicing that generates RNA encoding antagonistic proteins (Figure 1). Whether 
RNaseH activity takes place favorably in the cytoplasm or in the nucleus is not well 
documented. However, most studies suggest that the most part of the inhibition 
takes place in the cytoplasm. Controversially, ASOs that targets pre-mRNA and are 
splice modulators are active in the nucleus.
Figure 1. 
ASOs mechanism of action. (1) In the absence of ASO, normal gene and protein expression is maintained. 
(2) Formation of ASO-mRNA heteroduplex in cytoplasm induces activation of RNase H, leading to mRNA 
degradation or (3) steric interference of ribosomal assembly. Alternatively, ASO can enter the nucleus and 
regulate mRNA maturation by (4) inhibition of 5′ cap formation, (5) inhibition of mRNA splicing and  
(6) activation of RNase H.
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2.2 ASO’s design
There are several screening strategies to obtain potent ASO, such as using a compu-
tational algorithm in ASO design [10], mRNA walking [11], OD array [12] and RNase 
H mapping [13]. However, some of these approaches are labor intensive and require 
expensive automation equipment. Many factors can affect the strength and stability of 
the ASO-mRNA interaction, such as the mRNA secondary structure, thermodynamic 
stability and also the position of the hybridization site relative to functional motifs on 
the target RNA, such as the 5’ CAP region or translational start site.
To find a highly potent ASO, the “hit rate” can be increased by considering four 
parameters during ASO design:
2.2.1 Prediction of the secondary structure of the RNA
It is recognized that a secondary structure of the RNA accurately predicted, 
leads to effective ASO design [14, 15]. Some algorithm able to predict any single 
mRNA secondary structure and folding pattern are currently available, such as the 
mfold and the sfold program.
2.2.2 Identification of preferable RNA secondary local structures
In order for the ASO to be effective, it should target mRNA regions accessible 
to hybridization [16], such as joint sequences, internal loops, and hairpins of 10 or 
more consecutive nucleotides, usually located at the terminal end of the sequence 
[17]. It has been shown that highly conserved motifs are a good target of a potent 
ASO, whereas ASO targeting variable local motifs may induce non-sequence 
specific effects [18]. Therefore, the best approach to increase the ‘hit rate’ of potent 
ASO design is to target these conserved motifs among several optimal mRNA 
predicted secondary structures.
2.2.3 Motifs searching and GC content calculation
Although RNase activity is stimulated by the formation of the ASO-mRNA het-
eroduplex, leading to the mRNA degradation, it has been shown that this activity 
occurs independently of the ASO sequence, but is rather strongly correlated to the 
GC content which is also known to affect thermodynamic stability.
The perfect content of GC is still controversial; it is described that a strong ASO 
effect is observed with a percentage of 45–65% of G or C residues [10]; however, 
many of the ASOs used in therapy today do not have a GC content in this range.
2.2.4 Binding energy prediction
Thermodynamic energy is also important to a successful ASO design. Some 
available software can calculate thermodynamic properties between the target 
mRNA sequence and the ASO. To design a potent ASO, the binding energy between 
the ASO and mRNA should be DG37 ≥ −8 kcal/mol, whereas the energy for binding 
between ASOs should be DG37 ≥ −1.1 kcal/mol [19].
2.3 ASO’s chemical modification
The use of unmodified ASOs is limited as they have an overall charged property 
that prevents them from getting through the cell membrane and are rapidly attacked 
by all types of intracellular endonucleases and exonucleases, usually via 3′-5′ activity 
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in biological fluid. In addition, the degradation products of phosphodiester ODs 
may be cytotoxic and also exert anti-proliferative effects. Moreover, some unspecific 
hybridization has been observed and finally for most applications immunostimula-
tion has also been a matter of concern [20, 21]. This part will be further detailed in 
the toxicity chapter.
Numerous chemical modifications have been developed to improve nuclease 
resistance, extend tissue half-life, reduce non-sequence-specific toxicity, as well as 
to increase affinity and potency (Figure 2).
2.3.1 First-generation ASO
First-generation ASOs are the ones having a phosphorothioate (PTO) modi-
fied backbone. These ASOs have a sulfur atom that substitutes the non-bridging 
oxygen atoms in the phosphodiester bond [22] (Figure 2a). PTO modification 
confers higher resistance to the ASO against nuclease degradation, leading to higher 
bioavailability. Additionally, they are highly soluble and have excellent antisense 
activity [23]. Finally, PTO-modified ASOs promote degradation of target mRNA by 
RNase H enzyme. Nevertheless, this modification may slightly reduce the affin-
ity of the ASO for its mRNA target because the melting temperature (Tm) of the 
ASO-mRNA heteroduplex is decreased [20]. PTO modification is the most widely 
Figure 2. 
Chemical modifications of ASO. (a) First-generation PTO, (b) second generation, RNase H cleavage induced 
by chimeric ASO, and (c–e) third-generation ASO.
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performed chemical modification of ASOs for loss-of-function studies in vitro 
and in vivo for gene target identification and validation. These data have led to the 
introduction of PTO ASOs into clinical therapeutic trials. Indeed, Fomivirsen, a cur-
rently FDA approved drug for clinical use, is a first-generation PTO-modified ASO 
[24]. Despite the fact the PTO modifications are the most widely used ODs, they 
have many properties which render them suboptimal antisense effector molecules. 
The PTO backbone is known to induce sequence-independent effects attributable to 
its length dependent high affinity for various cellular proteins. However, this seem-
ingly negative property of PTO ASOs to interact with certain proteins proved to 
be advantageous for the pharmacokinetic profile. Their binding to plasma proteins 
protects them from filtration and is responsible for an increased serum half-life [25]. 
Finally, these oligonucleotides can interact with components of the innate immune 
system such as Toll-like receptors (TLRs), inducing an immune response and 
triggering cytokines expression and other genes coding for the nonspecific defense 
mechanisms [26].
Nevertheless, to try to solve the several non-specific problems [27], new 
chemical modifications have been developed. Modifications to the base, sugar and 
backbone have been identified that increase binding affinity for the target RNA.
2.3.2 Second-generation ASO
The second generation represents oligonucleotides in which the structural 
modification is not limited to the backbone linkage but additionally includes 
structural modifications of the ribose: ASO with 2’-O-alkyl modifications of 
the ribose were developed (Figure 2b). These modifications intend to improve 
binding affinity, to increase efficacy, to modulate the protein binding of oli-
gonucleotides and to enhance nuclease resistance. 2’-O-Methyl (2’-OMe) and 
2’-O-Methoxyethyl (2’-MOE) modifications of ASO-PTO are the most widely 
studied [28]. These second-generation ASOs are less toxic than PTO- modified 
ASOs and have a slightly enhanced affinity towards their complementary RNAs 
[29]. Moreover, an important aspect for these ASOs is that 2’modifications can 
reduce immunostimulatory effect [30]. However, 2’-OMe and 2’-MOE substitu-
tions do not activate the RNase H to cleave the target mRNA, which decreases 
the efficacy of the ASO [31]. Indeed, mechanistic studies have been conducted to 
elucidate RNase H activity. They have shown that the flexibility of the ASO, the 
accessibility of the 2′-OH group of the RNA and the correct width of the minor 
groove of the ASO-RNA duplex are necessary for effective RNase H mediated 
mRNA degradation [32]. Since 2′-O-alkyl RNA ODs do not activate the RNase 
H, they inhibit mRNA expression only by a steric interference with translation. 
However, to increase its potency, an ASO should be able to induce cleavage by 
RNase H. Therefore, a chimeric ASO was developed (Figure 2b). It consists of a 
central ‘gap’ region containing 10 DNA or PTO DNA monomers and flanked on 
both sides (5’and 3’extremities) by approximatively 5 modified nucleotides such as 
2′-OM or 2’-MOE (indicated by red and yellow regions of the OD in Figure 2b). 
This chimeric ‘gapmer’ ASO allows RNase H to sit in the central gap and to execute 
target-specific mRNA degradation; meanwhile, the flanking 2′-alkyl modified 
ends prevent nuclease cleavage of ASO. The 2′-O-MOE-PTO gapmers OGX-427 
(Apatorsen) developed by Rocchi et al., directed against HSP27 and OGX-011 
(Curtisen) against clusterin are currently undergoing clinical trials (Table 1). The 
ODs being tested clinically mainly incorporate relatively simple chemical modifi-
cations such as the PTO modifications and the 2′-alkyl modifications (first- and 
second-generation ODs).
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2.3.3 Third-generation ASO
Third-generation ASOs have been developed to further improve nuclease resis-
tance, increase binding affinity, and to enhance pharmacokinetics and biostability. 
They are characterized by chemical modifications of the nucleotide, and more 
precisely to its furanose ring [33]. Many modifications have been described, such as 
N3′-P5′ phosphoramidates, 2′-deoxy-2′-fluoro-β-D-arabino nucleic acid analogue 
(FANA), cyclohexene nucleic acids (CeNAs) and tricyclo-DNA (tcDNA), however, 
peptide nucleic acid (PNA), phosphoramidate morpholino oligomer (PMO) and 
locked nucleic acid (LNA) are the three most studied third-generation ASOs [34, 35].
It should be noted that there is no single modification that covers all the desired 
properties for a modified ASO. As described before, chemical modifications can 
improve ASO-RNA hybridization affinity, enhance nuclease resistance, decrease toxic-
ity and modulate pharmacokinetics. An optimal antisense can be designed depending 
on its use by mixing and matching the numerous chemical modifications accordingly.
2.3.3.1 Peptide nucleic acid
PNA is a synthetic DNA mimic in which the deoxyribose phosphate backbone is 
replaced by polyamide linkages [36] (Figure 2c). PNAs are biologically very stable 
and have good hybridization properties. However, they do not activate mRNA cleav-
age via RNase activity, but rather block translation and thus protein expression, by 
forming sequence-specific duplex with mRNA, hence generating steric hindrance. 
Due to their neutral backbone, PNAs have low solubility and their cellular uptake 
remains a challenge for exploiting them as therapeutics antisense. PNAs delivery 
can be enhanced annealing a PNA strand with a negatively charged complementary 
oligonucleotide, and then enclosed the obtained duplex with a cationic lipid. To this 
end, PNAs are also conjugated to peptides for improving their cellular uptake [37, 38]. 
Furthermore, PNA can elicit antigen effects by hybridizing with double-stranded 
DNA [36, 39] resulting in transcriptional arrest. Substantial data have revealed the 
effectiveness of PNA in gene silencing in various in vitro models [39, 40].
2.3.3.2 Phosphoramidate morpholino oligomer
PMOs are non-charged ASOs whose pentose sugar is substituted by a morpho-
lino ring and the inter-nucleotide linkages are phosphoramidate bonds in place of 
phosphodiester bonds [41] (Figure 2d). PMOs avoid the RNase H recruitment; their 
effect is primarily mediated by steric interference of ribosomal assembly resulting in 
translational arrest. Synthetic PMOs are resistant to nucleases degradation in biologi-
cal fluid. Because their backbone is uncharged, PMOs are unlikely to form unwanted 
interactions with nucleic acid-binding proteins [42]. PMOs do not enter mammalian 
cells easily in culture, but it has been shown that conjugating it with peptides such  
as arginine-rich peptide (ARP) can enhance its cellular uptake and antisense potency 
[43]. Antisense PMO oligonucleotide, have shown efficacy in animal models in vivo 
and in human clinical trials [44, 45]. Indeed, a PMO antisense agent is currently in 
phase II clinical trials for restenosis, cancer and polycystic kidney disease.
2.3.3.3 Locked nucleic acid
Locked nucleic acids oligonucleotides figure among the most promising candi-
dates developed the last few years. LNAs are chemically modified nucleotides with 
a ribose containing a methylene bridge between the 2′-oxygen and the 4′-carbon 
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of the ribose [46]. LNA modifications improve significantly the ASO hybridization 
affinity towards mRNA target, due to the important increase in the thermal stability 
of the DNA/RNA heteroduplexes [47]. In addition, LNAs avoid nuclease degrada-
tion. As their ribose 2’-O position are modified, LNAs are not recruiting RNase H 
[48]. Nevertheless LNA nucleotides can be freely incorporated at the ends of RNA 
and DNA sequences to form chimeric oligonucleotides resulting in restoration of 
RNase H-mediated cleavage of mRNA. It has been shown that the chimeric LNA/
DNA/LNA gapmer with seven to 10 phosphorothioate-modified DNA central gaps 
flanked by three to four LNA nucleotides on both 5′-end and 3’ends induces efficient 
mRNA cleavage, because of their high target affinity and nuclease resistance [29]. 
In the first in vivo study reported, the LNA ASOs appeared to be nontoxic in the 
optimal dosage. Therefore, full LNA and gapmers LNA·DNA·LNA ASOs seem to 
offer an attractive set of properties, such as potent biological activity and appar-
ent lack of acute toxicity, making it a promising antisense agents [49–51]. Table 2 
recapitulates the chemical modifications characteristics.
Despite the large number of molecules being evaluated in the clinical trials, 
the clinical progress of ASOs had to face many challenges; indeed, poor pharma-
cokinetics [52], poor cell membrane permeation [53], and off-target effects [27]. 
Last decade, the development of oligonucleotide delivery through lipid or polymer 
systems has improved the cellular uptake and the pharmacokinetic behavior [54].
3. ASO’s pharmacokinetics, toxicity and delivery
3.1 ASO’s pharmacokinetics and toxicity
The pharmacokinetics of ASOs has been extensively studied; they rapidly 
distribute to all tissues in vivo [55]. First and second-generation PTO ODs are 
broadly distributed to all peripheral tissues. The highest concentrations of ODs are 
found in the liver, kidney, spleen, lymph nodes and bone marrow with no measur-
able distribution to the brain [52]. Moreover, they not only distribute to tissues 
but also accumulate within cells in tissues [56]. The mechanism(s) by which ODs 
accumulate within cells following parenteral administration is currently unknown 
[57]. However, ODs that do not contain a PTO linkage appear to be rapidly excreted 
in the urine [58]. This difference in tissue distribution appears to be due largely to 
interactions with plasma proteins.
Table 2. 
Chemical modification characteristics.
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In summary, pharmacokinetic studies of PTO ASO demonstrate that they are 
well absorbed from parenteral sites, distribute broadly to all peripheral tissues, 
do not cross the blood-brain barrier (BBB), and are eliminated primarily by slow 
metabolism. Altogether, their pharmacokinetic properties depend on chemistry 
rather than sequence.
Concerning ASO’s toxicity, there are two broad categories of potential toxicities 
for ASOs; toxicities due to exaggerated pharmacology and toxicities due to non-
antisense effects of the ASO. The former category of side effects results from the 
ASO binding to off-target RNA, producing an undesirable effect. The potential for 
such toxicities can be further minimized by vigilant selection of the drug target and 
homology searches against human genomic databases. The second category of poten-
tial toxicities (non-antisense effects) has been documented at higher doses of ASOs. 
In clinical trials PTO ASOs have proven to be safer than originally anticipated [31, 34, 
35]. ASOs drugs principally induce mild-to-moderate toxicities related to the admin-
istered dose. In vivo, the two mains mechanism that induce acute toxicity through 
ASOs administration are for the first one the activation of the transient complement 
cascade and for the second one the inhibition of the clotting cascade. The increase 
in the clotting times is defined by a transient concentration-dependent escalation of 
activated partial thromboplastin times (aPTT) [59]. Another frequently occurring 
sub chronic toxicity is immune stimulation, manifested as splenomegaly, lymphoid 
hyperplasia and diffused multi-organ mixed mononuclear cell infiltrates [60]. This 
is due to an unmethylated cytosine-phosphorous-guanine (CpG) motif in the ASO 
sequence that can be recognized by Toll-like receptor (TLR)-9 in immune cells. This 
results in the release of cytokines, interleukin (IL)-6, IL-12, interferon (INF)-γ), B 
cell proliferation, antibody production and activation of T lymphocyte and natural 
killer (NK) cells [61]. In order to avoid the immune response, the cytosine of the 
sequences including CpG motif are substituted by methylated cytosine. Also, for 
preventing this side-effect, the sequences of ASOs drug can be designed without 
CpG motif. These both stimulatory immune responses are related to the sequence 
and the chemical modification of the ASOs [6]. Indeed, second-generation ASOs 
have been shown to have smaller immune stimulation that ASOs PTO. In addition, 
introduction of LNA into the PTO-ASO has been shown to reduce, and even elimi-
nate, CpG dinucleotide-mediated immunostimulation [62, 63]. When ASO’s plasma 
concentration is high, some toxicities have been observed, such as elevated liver 
enzyme such as aspartate aminotransferase (AST) and alanine amino-transferase 
(ALT), thrombocytopenia, and hyperglycemia [52].
3.2 ASO’s delivery
Although the clinical relevance of ASOs has been demonstrated, inefficient 
cellular uptake, both in vitro and in vivo, limit the efficacy of ASOs and has been a 
barrier to therapeutic development. Cellular uptake can be <2% of the dose result-
ing in too low ASO concentration at the active site for an effective and sustained 
outcome [22]. Indeed, many researches are conducted on the improvement of ASO 
delivery via the use of delivery vehicles.
3.2.1 Mechanism of cellular uptake
Cellular uptake refers to the combination of both OD membrane-binding and 
internalization. It is challenged by numerous barriers, most importantly, the lipo-
philic nature of the cell membrane, which makes the passage of these large anionic 
molecules complicated. Several barriers to cellular uptake exist such as the lipophilic 
cell membrane, through which these large, anionic molecules must pass to reach the 
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site of action. In cultured cells, the internalization of naked ASOs is generally ineffi-
cient, with only a few ASO molecules actually penetrating the cell [21]. Exogenously 
administered ASOs enter cells in vitro by a combination of fluid-phase (pinocytosis), 
caveolae potocytosis, adsorptive and receptor-mediated endocytosis (Figure 3),  
cellular uptake mechanisms being different depending on the ASO chemical struc-
ture. However, this results in a trafficking problem because not all of the internalized 
ASO will be able to reach their target and interact with it. This is because the majority 
of internalized ASO is sequestered into endosome or lysosomal compartments [21]. 
A significant amount of the OD is also compartmentalized within other cellular 
organelles, such as the Golgi complex and the endoplasmic reticulum [64].
To improve cellular uptake and OD’s activity, a range of techniques and trans-
porters have been developed [65, 66]. Simultaneously, the use of these vectors 
increases the stability of ODs against nuclease digestion and allows the use of lower 
concentrations of ODs.
3.2.2 General delivery methods
OD delivery can occur through carrier molecules. Receptor-mediated endocytosis-
directed uptake utilizes import mechanisms already present in the cell membrane 
for the uptake of biomolecules necessary for cell function [67]. ODs can be linked 
directly to a carrier protein via a covalent bond or non-covalently via poly-L-lysine 
(PLL)-carrier conjugates. The choice of the carrier is dependent on its known ability 
to bind to specific cell membrane receptors and accumulate in the cell via endocytosis. 
Not only OD’s internalization can be potentially improved, but cell-specific delivery 
can also be achieved by targeting receptors exclusively expressed or over-expressed 
on certain target cells. However, the OD is generally sequestrated in endosomal 
compartments, thereby limiting the utility of this method for delivery [22]. The use of 
peptides can help overcome this issue. Indeed, as peptides have membrane transloca-
tion properties, they can increase ODs passage through the plasma membrane. For 
example, fusogenic peptides have been used to promote peptide fusion of OD-peptide 
conjugates with either cell or lysosomal membranes [68]. To facilitate OD transport 
to the nucleus, nuclear localization signals (NLS) can be used for ODs that inhibit 
pre mRNA splicing [69]. Another peptide used is CPP, a short peptide sequence 
Figure 3. 
Cellular uptake and intracellular trafficking of oligonucleotides. Oligonucleotides enter cells via several 
endocytotic pathways. Most of ODs are recycled in early recycling endosomes. ODs accumulate in endosomes, 
multivesicular bodies (MVB) and lysosomes. A significant amount is compartmentalized in cellular organelles 
like the trans Golgi network (TGN).
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(<30 amino acids) with net positive charge that uses an energy dependent pathway 
to allow internalization of large molecules like ASOs. Commonly used CPP include 
penetratin, HIV TAT peptide and transportan. Through disulfide bond, ASOs and 
CPP can be conjugated. To evaluate ASO-CPP effect on mRNA degradation in vitro 
and in vivo, PNA is the most used [43, 70, 71]. An interesting variation is to couple 
two different ASOs to a single CPP thus addressing two targets simultaneously [72]. 
The most dramatic advance in OD targeting has involved delivery via the asialogly-
coprotein receptors (ASGR). ASGPR, also known as the Ashwell receptor, is a lectin 
that is abundantly expressed on hepatocytes [73] and clears serum glycoproteins by 
receptor-mediated endocytosis [74]. The functional receptor is a trimer comprised 
of two proteins and exhibits high affinity for N-acetyl galactosamine (GalNAc) 
terminated oligosaccharides [75]. A major breakthrough came from researchers who 
developed multivalent GalNac conjugated siRNAs that bind to the ASGR [76]. The 
conjugates were effectively taken up into primary mouse hepatocytes by a receptor-
specific mechanism, leading to silencing of targeted genes. GalNac based conjugates 
have similarly been used to transport ASOs to the liver in mice with good effects on 
reduction of target gene expression [77]. Indeed, GalNac-ASOs showed high affin-
ity for mouse ASGPR, which resulted in enhanced ASO delivery to hepatocytes. 
Furthermore, once inside the cell, GalNac-ASO’s metabolism leads to ASO release 
in the liver, thus acting like a prodrug targeting hepatocytes. Moreover it improved 
potency and extent the effect of both antisense targeting human transthyretin (TTR) 
and human apolipoprotein C-III in transgenic mice. This study highlighted several 
of the virtues of conjugates including use of a molecularly defined entity, high tissue 
and cell selectivity and lack of substantial toxicity. The successes with glycoconjugates 
in the laboratory have facilitated their rapid translation to clinical evaluation, with 
several hepatic genes being addressed. Finally, an additional approach to OD internal-
ization is to generate transient permeabilization of the plasma membrane and allow 
naked ODs to penetrate into the cells by diffusion. It consists of inducing transitory 
pores in the membrane, either chemically by streptolysin-O-permeabilization, 
mechanically by microinjection, or by electroporation [78] or ultrasound.
All of these methods, under defined circumstances, can permit charged or 
uncharged ODs to enter cells rapidly and localize in the nucleus, where they pro-
duce antisense inhibition of gene function.
Nevertheless, one of the most promising strategies used to overcome cellular 
barriers is the use of nanotechnology. Indeed, nanocarriers offer the possibility to 
encapsulate drugs but also nucleic acid, to protect it from degradation, enhance its 
distribution to the tissues and the cells, but also reduce toxicity and thus second-
ary effects by targeting specific organs. It is a very promising tool for combination 
therapy and theranostics applications. To bypass the limitations of ASO-based 
therapy, like insufficient stability and low intracellular delivery and distribution, 
Dr. Rocchi’s lab recently developed a modified first-generation ASO by using 
a lipid-conjugated oligonucleotide modification (LASO) able to overcome the 
problems to ASO administration. The idea is to improve ASO’s stability, efficiency 
and biodisponibility by adding a hydrophobic lipid chain at the 5’end of the hydro-
philic DNA sequence. As amphiphiles, LASOs self-assemble in aqueous media with 
an encapsulation rate of 100%, which yields in small spherical objects of ~11 nm 
in diameter [79]. Due to their small size, these nanomicelles, can accumulate 
inside the tumor via EPR effect (enhanced permeability and retention effect), 
which permits passive targeting and reduced systemic toxicity. Interestingly, 
transfection with these lipid-modified ASO leads to rapid and prolonged internal-
ization via micropinocytosis with no transfecting agent. Interestingly, the addition 
of the lipid, does not affect LASO’s efficacy in vitro and in vivo with little or no 
toxicity in animal models.
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4. Discussion/conclusion
Antisense oligonucleotide based therapies are promising. They can be used for 
human therapy and can specifically inhibit target genes. Despite the promising 
progress since their discovery, only a few have been approved for clinical use. This 
low success rate can be explained by their anionic charge which prevents them 
from getting through the cell membrane and are rapidly destroyed by nuclease. To 
address these problems many chemical modifications have been developed. Finally, 
improvement of their delivery to the tissues, and thus their efficacy is an important 
issue that has to be addressed. To solve this problem, many strategies have been 
studied; nanotechnology is one of the most promising to overcome the cellular 
barriers for the ASO delivery towards targeted therapy.
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